Objective: Acute myeloid leukemia is the most lethal leukemia among blood cancers. Its prevalence is 3 to 4 per 100,000 people, and the number of people infected increases annually. Understanding its molecular mechanism can play an important role in the diagnosis and treatment of this disease. Considering this issue, in the present study, we have tried to study the current paths with further investigation. The expression of miR-181a and miR-155 in patients and cell lines have been analyzed. Material and Methods: In this study, 4 NB-4, U-937, KG-1 and HL-60 cells were classified as AML (acute myeloid leukemia) and 15 AML patients and 15 samples as controls for this study were used. One-way ANOVA and t-test were used to analyze the data and also to evaluate the expression of Real-Time PCR. Results: Our studies showed that the expression of miR-181a, that is a tumor suppressor, is increased in patients with the more progressive disease, which in the subsequent studies indicates a prognostic role of this miRNA. Expression of the cells in the form of acute forms was also high. In the case of miR-155, which was also an oncogenic membrane, expression in both cell and human cells increased in comparison to the control sample. Conclusion: The present study showed that the highest the severity of the disease, the increased expression of miR-181a, which was raised in those who were treated and declined, the survival rate was highest. While the expression of miR-155 reduced the amount of cell proliferation with effect on cyclin factors. Possibly by controlling some of these miRNAs, one can expect better treatments. Corresponding author Email address: mkoolivand14@gmail.com
کلید واژگان :Acute myelogenous leukemia, miR-155, miR-181a, cancer
ارزش ریالی : 350000 ریال
با پرداخت الکترونیک